Transplantation and Cellular Therapy
Publisher: Elsevier · ISSN 2666-6367 · 87 articles
- Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia
- Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation
- Absence of Pretransplant Peripheral Blasts is Favorable Factor in Allogeneic Stem Cell Transplantation for Advanced Acute Lymphoblastic Leukemia
- A longitudinal investigation of the financial impact of receiving chimeric antigen receptor t-cell therapy
- A Retrospective Study Evaluating the Efficacy of Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor with/without Idarubicin Followed by Second Allogeneic Stem Cell Transplant in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia/Myelodysplastic Syndrome Following First Allogeneic Stem Cell Transplant
- Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity
- International Survey and Next-Generation Sequencing-Based Indel Chimerism Detection of Human Leukocyte Antigens Loss in Relapsed Haploidentical and Mismatched Unrelated Donor Transplant Recipients
- Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status
- Discontinuing Ciprofloxacin Prophylaxis in Allogeneic Stem Cell Transplantation Does Not Result in Inferior Outcomes
- Feasibility of 8 Gy TBI-Busulfan-Fludarabine Conditioning With Post-Transplant Cyclophosphamide for Pediatric High-Risk or Relapsed Acute Lymphoblastic Leukemia
- High Predicted Thiotepa Exposure is Associated with Increased Risk of Thrombotic Microangiopathy and Non-Relapse Mortality in Pediatric Patients Undergoing Alpha-Beta T-Cell Depleted Haploidentical Transplantation
- Overcoming Donor-Specific Anti-Human Leukocyte Antigen Antibodies With Desensitization in Adult Ex-Vivo T-Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation: A Real-World Analysis
- Haploidentical Hematopoietic Stem Cell Transplantation Drives Time-dependent premature T Cell Senescence: Recipient Microenvironment Modulates Donor T Cell Epigenetic Aging, Telomere Homeostasis and SASP Remodeling
- Association of a Digital Clinical Decision Support Platform With Early Outcomes After Pediatric Allogeneic Hematopoietic Cell Transplantation: A Three-Era Guideline Implementation Cohort Study
- The Role of Physical Therapy Across the Transplant Trajectory in Allogeneic Hematopoietic Stem Cell Transplantation, A Systematic Review and Clinical Framework
- Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-Adapted Prevention Strategy
- Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
- Real-World Use of Maribavir for Refractory CMV Infection and Intolerance to Conventional Anti-CMV Agents After Allogeneic Hematopoietic Cell Transplantation
- Trends and Disparities in Chimeric Antigen Receptor T-Cell Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017 to 2022)
- Clinical Trials in Graft-Versus-Host Disease: Changes in Study Characteristics, Investigated Drugs, and Endpoints Over Time
- Prospective Validation of Multiweek Inpatient Census Forecasting for Pediatric HSCT and Cellular Therapy
- Autologous Stem Cell Transplantation, Chimeric Antigen Receptor T Cell Therapy, or Combined Consolidation for Relapsed/Refractive Primary Central Nervous System Lymphoma in Reachieved Complete Remission: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study
- Exercise Duration during a Brief Step Test Independently Predicts Outcomes after Hematopoietic Cell Transplantation
- The Effect of Belumosudil on the Therapeutic Drug Levels of Tacrolimus and Sirolimus in Allogeneic Hematopoietic Transplantation
- Comment on “Tooth Loss and Oral Health-Related Quality of Life in a Subcohort within the Chronic Graft-versus-Host Disease Consortium”
- Comment on “Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity”
- Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation
- Comment on “Immune Reconstitution After Allogeneic Stem Cell Transplantation: Time Alone Does Not Heal All Wounds”
- An Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients